Friday, May 14, 2021

UHS begins trial for another coronavirus vaccine from China next week

Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click. Combine them, rearrange them and customize them further as much as you desire. Welcome to the future of building with WordPress.

Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click. Combine them, rearrange them and customize them further as much as you desire. Welcome to the future of building with WordPress.

Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click. Combine them, rearrange them and customize them further as much as you desire. Welcome to the future of building with WordPress.

UHS is ready to launch a second test vaccine. The CanoSino coronavirus vaccine was developed by the Beijing Institute of Biotechnology. The previous UHS study for the CanoSino vaccine enrolled 18,000 helpers and at a later date.

The University of Health Sciences (UHS) is ready to begin Phase III studies on another Chinese coronavirus vaccine.

UHS Deputy Chancellor Professor Javed Akram said the trial would start earlier next week.

Earlier this week, the Prime Minister’s (Imran Khan) Special Assistant for Health, Dr. Faisal Sultan, announced that “China’s CanoSino COVID-19 vaccine is generally 75% effective against the virus in Pakistan”.

On Twitter, the specialist assistant said that data from the three phases of the vaccine proved to be 74.8% effective against the virus, while it was shown to be 100% effective in preventing serious illness.

Citing a report from the independent Data Monitoring Committee, he also said the vaccines were 65.7% and 90.98% effective in many countries in preventing symptomatic cases and serious illnesses.

SAPM said IDMC had not reported a “serious safety issue” and its data including till 30,000 participants and 101 people who had tested positive for the coronavirus.

Phase III of coronavirus vaccine

The National Bioethics Committee VC approved a phase III, “involving humans” Shuffled, double-blind, placebo-controlled trial in people over 18 years of age to decide the safety and effectiveness of “ZF2001” – a recombinant novel coronavirus vaccine for prevention of COVID-19.

A double-blind study in which neither the participants nor the researcher know who is receiving a particular treatment. This procedure has used to check favoritism in the results of the study.

We are expecting the trial’s approval from Drug Regulatory Authority of Pakistan, during this week after which the recruitment of helper will start,” said Professor Akram, adding that 1,000 helpers would be registered for the test.

You can get guidance about registration from this link and especially registered frontline health workers can register themselves on it.

Each helper received three doses of the vaccination over three months. During these three months they had to visit the test site seven times.

The VC said, Rs 16,000 will paid for travel and food expenses. The process will end in 18 months, he added.

More From Latest News

Top Trending